The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.
Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.
Cure Parkinson’s is opening a new internship opportunity for young-career researchers to participate in our grant application process by joining our Research Committee.
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.
Our first project from our Research Pipeline Acceleration Programme is now underway. Professor Michael Schwarzchild is investigating evidence needed to determine if three iLCT-evaluated compounds are ready to progress into clinical trials for people with Parkinson’s.